Choose Layout

Choose Color

January 2019

In January’19, 57transactions were recorded, aggregatingtoUSD 1.8B. While the number of transactions were nearly same as in previous month (58 in Dec’18), but the value of transaction was nearly USD 1B lower than the previous month. In the previous month, of the total investment, US garnered nearly 64% investment (down from 96% in Dec), amounting to USD 1189M.Of the total 57 deals, 38 happened in the USA. It was followed by China, with 6 deals amounting to USD 355M. Among the top 3 deals value wise, 2 were from China. Israel and India share was nearly same. Both recorded 3 deals each, with USD 58M and USD 56M investment respectively. Indian deals were in BioPharma and formulations space respectively.

- Team Wisdomsmith


In previous month, Oncology and Gene Based Therapies garnered 19% and 18% share of deals, in terms of the value. BioPharma and Devices had 13% share each. They were followed by Digital Health and Health-Tech at 8% and 7% respectively. Other areas where deals happened were – Healthcare Services, Rare Diseases, and Auto Immune

Top deals of January’19:

BridgeBio is a company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of 19 transformative drugs ranging from pre-clinical to late stage development in multiple therapeutic areas including oncology, cardiology, dermatology, and endocrinology.

Recently BridgeBioand Cincinnati Children's Hospital Medical Center announced they are entering into a research collaboration to identify and develop genetic disease therapies. This partnership will combine BridgeBio's strengths in therapeutic development for diseases of high unmet need with Cincinnati Children's world-class researchers and clinicians.

Founded in 2017, Antengene Corporation (Antengene), a clinical stage therapeutics / biopharmaceutical company, which is focused on oncology. It’s focus is on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands.

Antengene's pipeline includes five clinical stage products, from phase2/3 and NDA stage ATG-010 for relapsed/refractory multiple myeloma, lymphomas and solid tumors; to ATG-008 that is in multi-regional clinical trial currently enrolling late stage HCC patients in Taiwan, S. Korea and mainland China. Two other phase 1 and phase 2 clinical stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527, studied in a completed phase 1 trial, is being explored for multiple anti-viral indications, including influenza, RSV, EB viral-related diseases

Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to eradicate the cancer. Funding would be used for advancing multiple oncology programs, exploring new treatment areas, increasing the pipeline of assets.

The company’s existing pipeline consists of six development-stage assets including three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and three targeted therapies against uncontrolled growth signaling pathways.

Black Diamond Therapeutics Inc. is a leading biotechnology company focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.

Oncogenes are activated by kinase domain mutations or by allosteric mutations. While kinase domain mutations have been successfully drugged with selective inhibitors and are standard of care in many malignancies, allosteric mutations represent an un-drugged and unexplored space. The fundamental discovery underlying Black Diamond is there are whole sets of oncogenic lesions outside the ATP binding site that are activated by common mechanisms and are inhibited by a single class of its drugs. Its platform generates single molecules able to treat entire baskets of mutations that otherwise would have been deemed unactionable

Ablative Solutions is a clinical-stage medical device start-up that is pioneering the novel approach of Transcatheter Perivascular Alcohol Denervation for the treatment of hypertension.

Ablative Solutions has developed the Peregrine System to perform chemical renal denervation, using alcohol as the neurolytic agent, which may have substantial advantages over energy-based systems. The Peregrine System Infusion Catheter features three equally spaced micro-needles that enable the controlled infusion of a neurolytic agent directly into the perivascular space around the renal arteries, where the sympathetic nerves reside.

Global leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company which has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients.

SOPHiA AI leverages statistical inference, pattern recognition and machine learning to maximize the value of genomics and radiomics data. Its deep experience in life science technologies and exposure to millions of diverse and complex data sets make SOPHiA a truly unique AI. SOPHiA’s exceptional ability to solve complex problems is outstanding for pinpointing the signal in the noise and characterizing the actionable findings to empower decision making. SOPHiA is already adopted and trusted by geneticists, pathologists and radiologists in over 850 leading hospitals worldwide.

Mid-Atlantic Dental Partners is a growing regional dental support organization (DSO) founded on the principle that high quality dental care requires a three-way partnership between the patient, the dentist and their support organization. An effective DSO must enable the dental team to focus all their attention on their patients while taking responsibility for all of the practices’ non-clinical activities.

These services include billing, collections, scheduling, clinical data analytics, group purchasing, marketing and assisting each practice in recruiting dental professionals. Mid-Atlantic Dental Partners is also committed to assuring each dentist clinical autonomy while improving the lifestyle of its dental partners and their staffs.

Ribon Therapeutics, a biotechnology company, is developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. Fresh funding will be used to advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors. Funding was led by the Novartis Venture Fund.

It is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and its proprietary discovery platform, it is building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Its lead program is developing PARP7 inhibitors for the treatment of cancer.

Caplin Point Laboratories Limited is a niche Pharmaceutical Public Limited Company head quartered in Chennai, India, manufacturing a wide range of Pharmaceutical Formulations. It predominantly to emerging markets in Latin America, Africa, and South East Asia

Vyome Therapeutics Inc. is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.

Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The lead molecule (VB 1953), which targets the huge unmet need in the drug resistant acne prescription market, is currently being evaluated in clinical trials in the United States.